BAX · Baxter International Inc
Market Cap
$13.35B
Shares
517.00M
BAX metrics
79 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$25.83
Market cap
$13.35B
Price action
19 metricsPrice change (1W)
-1.1%
Price change (30D)
-7.0%
Price change (3M)
+33.3%
Price change (6M)
+46.0%
Price change (YTD)
+35.2%
Price change (1Y)
+9.5%
Trailing year
Price change (5Y)
-68.8%
52-week high
$28.35
52-week low
$15.80
Change from 52-week high
-8.9%
Change from 52-week low
+63.5%
Annualized volatility
43.4%
Beta
1.2
RSI (14D)
51.0
Price vs SMA 50
+4.5%
Price vs SMA 200
+27.0%
Avg volume (3M)
6.52M
Relative volume
0.5
Average dollar volume
$155.43M
Company
3 metricsSector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
517.00M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.2×
reciprocal yield 85.9%
P / book
2.2
reciprocal yield 46.5%
FCF yield
—
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
10.1
reciprocal yield 9.9%
Earnings yield
-8.0%
Historical valuation
8 metricsP / E historical average (3Y)
37.0×
reciprocal yield 2.7%
P / E historical average (5Y)
38.9×
reciprocal yield 2.6%
EV / revenue historical average (3Y)
2.0×
reciprocal yield 49.2%
EV / revenue historical average (5Y)
2.5×
reciprocal yield 40.4%
EV / EBIT historical average (3Y)
301.8×
reciprocal yield 0.3%
EV / EBIT historical average (5Y)
171.7×
reciprocal yield 0.6%
EV / EBITDA historical average (3Y)
22.3×
reciprocal yield 4.5%
EV / EBITDA historical average (5Y)
21.2×
reciprocal yield 4.7%
Dividends & buybacks
7 metricsDividend yield
0.2%
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
$0.04
Dividend growth YoY
-94.1%
Dividend growth streak
—
Last ex-dividend
2026-08-28
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-07-30
Profitability
9 metricsGross margin
30.1%
Operating margin
-2.4%
Trailing 12 months
Net margin
-9.3%
Gross profit (TTM)
$3.45B
Operating profit (TTM)
−$274.00M
Net income (TTM)
−$1.06B
Trailing 12 months
Diluted EPS (TTM)
$-2.09
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+5.3%
Year over year
Net income growth YoY
+38.5%
Revenue (TTM)
$11.47B
Trailing 12 months
EPS growth YoY
+33.3%
Shares change YoY
+0.8%
Year over year · more shares
Revenue CAGR (3Y)
+3.8%
Revenue CAGR (5Y)
-0.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
-26.4%
FCF CAGR (5Y)
-22.1%
Quality
14 metricsReturn on equity
-17.1%
Return on assets
-5.4%
Debt / equity
—
Current ratio
1.9
EBITDA (TTM)
$679.00M
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
-0.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$2.15B
Total assets
$19.79B
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
$1.32B
Capital expenditures (TTM)
$441.00M
R&D (TTM)
$512.00M
SG&A (TTM)
$2.93B
Stock compensation (TTM)
$115.00M
R&D / revenue
4.5%
Stock compensation / revenue
1.0%
Ownership (13F)
3 metrics13F filers
697
13F filer change QoQ
+26
Institutional ownership
108.9%
Short interest
3 metricsShort interest
4.6%
Latest settlement · 3.0 days to cover
Days to cover
3.0d
Short-squeeze score
56 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
10456
CUSIP
071813109
13F (30d)
330 filings
327 filers
Visit website
Investor relations